EVH Evolent Health Inc

Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates through two segments, Services and True Health. The Services segment provides value-based care services that include Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows and engages patients; population health performance that delivers patient-centric cost effective care; and delivery network alignments. This segment also offers specialty care management solutions that support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation, and specific market dynamics; and comprehensive health plan administrative services that helps providers assemble the complete infrastructure required to operate, manage, and capitalize on a variety of financial and administrative management services. The True Health segment operates a commercial health plan for small and large businesses in New Mexico. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.

Date	Price Target	Rating	Analyst
1/10/2025	$15.00	Buy	Needham
12/3/2024	$36.00 → $29.00	Buy	BTIG Research
11/8/2024	$38.00 → $16.00	Overweight → Equal-Weight	Stephens
10/11/2024	$35.00	Overweight	KeyBanc Capital Markets
8/9/2024	$28.00 → $33.00	Hold → Buy	Truist
4/22/2024	$40.00	Buy	Citigroup
3/1/2024	$45.00	Outperform	Oppenheimer
1/3/2024	$39.00	Overweight	Barclays
12/6/2023	$37.00	Mkt Outperform	JMP Securities
10/16/2023	$46.00	Buy	UBS

Evolent Health Inc

Recent Analyst Ratings for Evolent Health Inc

Evolent Health Inc Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Guertin Shawn M was granted 21,979 shares (SEC Form 4)

New insider Guertin Shawn M claimed no ownership of stock in the company (SEC Form 3)

Director Jelinek Richard M was granted 21,979 shares, increasing direct ownership by 152% to 36,437 units (SEC Form 4)

Director Scott Cheryl was granted 21,979 shares, increasing direct ownership by 43% to 73,476 units (SEC Form 4)

Director Springstubb Brendan B was granted 21,979 shares, increasing direct ownership by 82% to 48,821 units (SEC Form 4)

Director Glass Russell Monroe was granted 21,979 shares, increasing direct ownership by 154% to 36,251 units (SEC Form 4)

Director Barbarosh Craig A. was granted 21,979 shares, increasing direct ownership by 69% to 53,935 units (SEC Form 4)

Director Grua Peter J was granted 21,979 shares, increasing direct ownership by 117% to 40,728 units (SEC Form 4)

Director Keck Kim was granted 21,979 shares, increasing direct ownership by 56% to 61,501 units (SEC Form 4)

Director Ajayi Toyin was granted 21,979 shares, increasing direct ownership by 182% to 34,074 units (SEC Form 4)